bannerHON
img
HONnews
HONnews
img PATIENT / PARTICULIER img PROFESSIONNEL DE SANTE img WEBMESTRE img
img
 
img
HONcode sites
Khresmoi - new !
HONselect
News
Conferences
Images

Themes:
A B C D E F G H I
J K L M N O P Q
R S T U V W X Y Z
Browse archive:
2018: S A J J M A M F J
2017: D N O S

  Non-Opioid Treatment Approved for Opioid Withdrawal

By Scott Roberts

THURSDAY, May 17, 2018 (HealthDay News) -- Lucemyra (lofexidine hydrochloride) has been approved by the U.S. Food and Drug Administration to treat symptoms of opioid withdrawal.

Withdrawal from an opioid painkiller can trigger symptoms including anxiety, agitation, sleep problems, muscle aches, sweating, nausea, diarrhea and drug craving. To prevent such symptoms, doctors typically recommend slow withdrawal from the drug, the FDA said.

But in some cases, especially among people with opioid addiction (what the agency calls Opioid Use Disorder, or OUD), another opioid medication is substituted and its dose gradually reduced.

Lucemyra, among a class of drugs called selective alpha 2-adreneric receptor agonists, limits the body's output of norepinephrine. This hormone is believed to play a role in symptoms of opioid withdrawal, the FDA said.

"We know that the physical symptoms of opioid withdrawal can be one of the biggest barriers for patients seeking help and ultimately overcoming addiction," said FDA Commissioner Dr. Scott Gottlieb. "The FDA will continue to encourage the innovation and development of therapies to help those suffering from opioid addiction transition to lives of sobriety, as well as address the unfortunate stigma that's sometimes associated with the use of medication-assisted treatments."

The agency stressed that Lucemyra is not specifically approved for Opioid Use Disorder, and the drug's use shouldn't extend beyond 14 days.

Lucemyra's side effects could include low blood pressure, slowed heart rate, sleepiness and dizziness. Less common reactions could include fainting and abnormal heartbeat.

The drug has not been evaluated in people under age 17, the FDA said. The agency added that it's requiring 15 additional studies in both people and animals to evaluate factors such as longer-term use and the drug's effects on the liver.

Lucemyra is produced by US WorldMeds, based in Louisville.

More information

The FDA has more about this approval.

Copyright © 2018 HealthDay. All rights reserved. URL:http://consumer.healthday.com/Article.asp?AID=734015

Resources from HONselect: HONselect is the HON's medical search engine. It retrieves scientific articles, images, conferences and web sites on the selected subject.
Therapeutics
Dizziness
Heart
Muscles
Anxiety
Blood
Nausea
The list of medical terms above are retrieved automatically from the article.

Disclaimer: The text presented on this page is not a substitute for professional medical advice. It is for your information only and may not represent your true individual medical situation. Do not hesitate to consult your healthcare provider if you have any questions or concerns. Do not use this information to diagnose or treat a health problem or disease without consulting a qualified healthcare professional.
Be advised that HealthDay articles are derived from various sources and may not reflect your own country regulations. The Health On the Net Foundation does not endorse opinions, products, or services that may appear in HealthDay articles.


Home img About us img MediaCorner img HON newsletter img Site map img Ethical policies img Contact